15.6
Farmacokinetisch-farmacodynamische relatie: problemen
De empirische benadering van therapieoptimalisatie is gebaseerd op het correleren van de farmacologische respons met de toegediende dosis. Een dergeli…
The pharmacokinetic–pharmacodynamic, or PK–PD, relationship links the pharmacological response to drug concentration at the target site, as reflected in plasma drug levels.
Modeling can become complex due to the presence of racemic mixtures, the influence of protein binding, the impact of delayed distribution, the formation of active metabolites, and the development of acquired tolerance.
Many drugs are administered as racemic mixtures, in which only one active isomer drives the response, making the isomer ratio crucial to efficacy.
In addition, drug response correlates more accurately with unbound plasma concentration, as protein binding alters free drug levels and complicates PK–PD modeling.
Besides protein binding, many drugs act on extravascular tissue, requiring longer equilibration times and delaying the response.
Some drugs produce pharmacologically active metabolites in the body. The plasma levels of these metabolites may correlate better with therapeutic response than those of the parent drug.
Also, chronic use of some drugs may lead to acquired tolerance, either through enhanced metabolism or diminished response, altering the PK–PD relationship over time.
View the full transcript and gain access to JoVE Core videos
Q1: Why is unbound drug concentration more important than total plasma concentration in PK-PD modeling?
Drug response correlates more accurately with unbound plasma concentration because protein binding alters free drug levels available to act at the target site. Total plasma concentration includes both bound and unbound drug, but only unbound drug can produce a pharmacological effect. Variations in protein binding between patients complicate PK-PD modeling when based solely on total concentration measurements.
Q2: How do active metabolites complicate the relationship between drug concentration and therapeutic response?
Some drugs produce pharmacologically active metabolites in the body whose plasma levels may correlate better with therapeutic response than the parent drug itself. Basing the PK-PD relationship solely on parent drug concentration can obscure the true concentration-response relationship. Examples include imipramine, amitriptyline, and propranolol, where metabolite activity significantly contributes to the overall therapeutic effect.
Q3: What causes delayed response in drugs acting on extravascular tissues?
Many drugs act on extravascular tissue rather than plasma, requiring longer equilibration times between the plasma and the site of action. This distribution delay means the pharmacological response lags behind plasma drug concentration changes. For example, the anticoagulant effect of dicoumarol shows long delays because it is an indirect measure of drug effect at the tissue level.
Q4: Why does the isomer ratio matter in racemic drug mixtures?
Many drugs are administered as racemic mixtures containing two optically active enantiomers, but typically only one active isomer drives the pharmacological response. A change in the ratio of active to inactive isomers can lead to significant differences in pharmacological response and efficacy. The isomer ratio is therefore crucial to predicting and maintaining consistent therapeutic outcomes.
Q5: How does acquired tolerance alter the PK-PD relationship over time?
Chronic use of some drugs may lead to acquired tolerance through either enhanced metabolism or diminished pharmacodynamic response. Pharmacokinetic tolerance involves increased drug elimination, while pharmacodynamic tolerance reflects reduced tissue responsiveness. Both mechanisms alter the PK-PD relationship, meaning the same plasma concentration may produce a weaker effect with repeated dosing.
Q6: What advantage does PK-PD modeling offer over empirical dose-response approaches?
PK-PD modeling correlates pharmacological response with plasma drug concentration or body drug amount rather than administered dosage, providing more precise predictions. Empirical approaches are costly, time-consuming, and often yield poor correlation due to formulation factors and drug elimination variability. Modeling assumes response is proportional to drug concentration at the site of action, reflected in plasma levels.
Q7: How does the duration of therapeutic action sometimes exceed plasma drug concentration persistence?
In some drugs like reserpine, the therapeutic action outlasts the measurable plasma drug concentration, creating a disconnect between plasma levels and observed effect duration. This occurs when drugs bind tightly to tissue receptors or produce sustained biochemical changes that persist after the drug is eliminated. Understanding this relationship is essential for predicting dosing intervals and the influence of elimination half-life on effect duration.